1012-17-5

Basic information

• Product Name: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID
• Synonyms: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID;3-(4-chlorophenyl)-2-methylpropanoic acid
• CAS NO: 1012-17-5
• Molecular Formula: C₁₀H₁₁ClO₂
• Molecular Weight: 198.65
• Mol File: 1012-17-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID(1012-17-5)
• EPA Substance Registry System: 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID(1012-17-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 1012-17-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID is used as a pharmaceutical agent for inhibiting Rho-associated protein kinase. This inhibition can be beneficial in the treatment of various diseases where Rho-associated protein kinase plays a significant role in their progression or pathophysiology.
Used in Research Applications:
In the field of scientific research, 3-(4-CHLORO-PHENYL)-2-METHYL-PROPIONIC ACID serves as a valuable tool compound for studying the role of Rho-associated protein kinase in cellular processes and disease mechanisms. This can aid in the development of targeted therapies and a better understanding of the underlying biology of various conditions.

Upstream product

• 1745-18-2 1-allyl-4-chlorobenzene 
• 104-88-1 4-chlorobenzaldehyde 
• 1202-60-4 3-(4-chlorophenyl)-3-methyl-2-acrylic acid 

Downstream Products

• 117763-47-0 methyl 3-(4-chlorophenyl)-2-methylpropanoate 
• 1346513-46-9 C₂₂H₂₁ClO₂ 

Relevant articles and documents

Carbonylative Transformation of Allylarenes with CO Surrogates: Tunable Synthesis of 4-Arylbutanoic Acids, 2-Arylbutanoic Acids, and 4-Arylbutanals

In this Communication, procedures for the selective synthesis of 4-arylbutanoic acids, 2-arylbutanoic acids, and 4-arylbutanals from the same allylbenzenes have been developed. With formic acid or TFBen as the CO surrogate, reactions proceed selectively and effectively under carbon monoxide gas-free conditions.

Weak, bidentate chelating group assisted cross-coupling of C(sp3)-H bonds in aliphatic acid derivatives with aryltrifluoroborates

A protocol of Pd(ii)-catalyzed, weak bidentate directing group assisted β-C(sp3)-H activation/cross-coupling with organoboron reagents has been achieved, affording arylation of aliphatic acid derivatives that contain α-hydrogen atoms in moderate to good yields. The potential of this method for an asymmetric β-C(sp3)-H arylation via desymmetrization was also presented.

Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation

RXRα represents an intriguing and unique target for pharmacologic interventions. We recently showed that Sulindac and a designed analog could bind to RXRα and modulate its biological activity, including inhibition of the interaction of an N-terminally truncated RXRα (tRXRα) with the p85α regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K). Here we report the synthesis, testing and SAR of a series of novel analogs of Sulindac as potential modulators for inhibiting tRXRα-dependent AKT activation. A new compound 30 was identified to have improved biological activity.

A facile synthesis of 2-benzyloxy/2-(4-isopropylbenzyloxy)-2-methyl-3-(4- substituted phenyl)propanoic acid based insulin sensitizing agents: RSR 13-15 and PKR13-15

The title compounds (RSR13-15) and (PKR13-15) were prepared by the etherification of benzyl alcohol and 4-isopropylbenzyl alcohol respectively with ethyl-2-bromo-2-methyl-3-(4-substituted phenyl)propanoates in the presence of sodium hydride in THF followed by alkaline hydrolysis of the ethyl esters. The substituted propanoic acids used in this synthetic sequence were prepared by magnesium-methanol reduction of correspondingly substituted propenoic acids, which in turn were prepared via 'Perkin Reaction' of 4-substituted benzaldehydes with propanoic anhydride. The details of the synthetic sequence followed for the preparation of all these compounds having almost all the structural features required for a compound to act as a potent insulin sensitizing agent are reported. Birkhaeuser Boston 2004.